Pharmaceutical and life sciences dealmaking in October ran along three lines: artificial intelligence moving from analysis into molecule design and laboratory automation, manufacturers and distributors securing capacity and supply routes, and diagnostics companies tying themselves more closely to drug developers. The month’s largest transaction, Viatris’s $1.65 billion offer for Pacira BioSciences, showed that commercial-stage assets with established products still command serious money.
AI Proteins entered a research collaboration and licence agreement with Astellas to discover miniprotein therapeutics through computational de novo design. AI Proteins is eligible for more than $400 million in upfront and milestone payments, plus royalties on net sales, while Astellas holds exclusive worldwide rights to resulting candidates and will take them through development, regulatory and commercialisation. It is the same division of labour seen in September’s Earendil–Genentech deal: an AI-native company designs, and a large company carries the asset forward. On the clinical side, Oracle announced a non-binding agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for trials. Initial areas could include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases, with patient recruitment named as one of the biggest obstacles in clinical trials.
AI is also moving into the lab itself. Danaher is working with NVIDIA on autonomous science, combining its instrumentation, automation and laboratory workflow software with NVIDIA’s accelerated computing so that experiments inform models and models help design better experiments. In pathology, Lunit and Discovery Life Sciences will expand use of the Lunit SCOPE suite within Discovery’s biomarker and tissue analysis workflows for biopharma clients. Taken together, these deals apply AI at the molecule, the patient, the instrument and the tissue slide.
Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion. The deal adds EXPAREL for acute postsurgical pain and ZILRETTA for osteoarthritis knee pain, which Viatris said complement its fast-acting meloxicam opportunity and position it as a leader in non-opioid pain management. Viatris also pointed to Pacira’s U.S. commercial, market access, medical affairs and global R&D capabilities as part of the fit. In central nervous system disorders, AmyriAD Therapeutics acquired Recognify Life Sciences and its lead clinical-stage programme RL-007 (inidascamine), widening its cognition pipeline while keeping Ismidenon (AD-101) as its lead Alzheimer’s disease programme.
Manufacturing partnerships reflected demand for scale in biologics and cell therapy. LOTTE Biologics will manufacture drug substance for multiple Alvotech antibody biosimilars at its Syracuse, New York facility, which has 40,000 litres of bioreactor capacity and recently completed an unannounced FDA inspection with zero observations. The agreement expands Alvotech’s U.S.-based manufacturing footprint. In cell therapy, Made Scientific will deploy CARR Biosystems’ UniFuge single-use centrifugation systems across its Princeton, New Jersey, and East Norriton, Pennsylvania, facilities for mesenchymal stem cell and feeder cell manufacturing, targeting the harvest and wash step where large-volume allogeneic processes are often constrained. Meanwhile, Scinai Biopharma Services signed a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company, including about $5.1 million in committed base service fees and lifting Scinai’s committed customer orders to about $7.6 million, up roughly 300% from year-end 2025.
Distribution and supply-chain deals showed that getting product to patients is now a deal category in its own right. AtomVie Global Radiopharma partnered with Jubilant Radiopharma for logistics, regulatory and last-mile distribution of its radiopharmaceuticals across Jubilant’s U.S. pharmacy network. In Canada, Mint Pharmaceuticals expanded its distribution partnership with Bayer to include ANGELIQ, the CLIMARA and TRIQUILAR ranges and XARELTO granules for oral suspension. At national level, BD announced a partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables.
Precision medicine and oncology research drew a cluster of collaborations. SOPHiA GENETICS and Myriad Genetics are collaborating on PrGIS, a prostate cancer-specific genomic instability score tied to homologous recombination deficiency, with the aim of advancing it in clinical trials and toward potential companion diagnostics alongside AstraZeneca. CellCarta and Waters set up a strategic partnership to pursue companion diagnostic and next-generation flow cytometry opportunities with drug developers, starting with flow cytometry-based programmes. 10x Genomics launched a multi-project collaboration with Fred Hutchinson Cancer Center, its first clinical research initiative to extend beyond solid tumours into blood cancers. In Taiwan, PurMinds signed a collaboration with SpectroChip and Kaohsiung Municipal Siaogang Hospital to establish a joint clinical validation testing centre for point-of-care diagnostics, subject to institutional review board and regulatory approvals.
Ecosystem and regional partnerships rounded out the month. CHIME and ScaleHealth formed a joint venture, ScaleHealth, powered by CHIME, to connect healthcare organisations with entrepreneurs, technology companies and investors. Cognito Therapeutics and the Rhode Island Life Science Hub launched the Rhode Island Brain Health Collaboratory, the third in Cognito’s national network after West Virginia University’s Rockefeller Neuroscience Institute in 2025 and Ochsner Health in 2026, to evaluate its Spectris platform in Alzheimer’s disease and other neurological conditions. In Asia, the Malaysia Healthcare Travel Council and Maybank formalised a multi-year collaboration to bring the Malaysia Healthcare ecosystem to Maybank customers across ASEAN, and in the U.S. NNPEN and Nurse Approved Certification partnered to give nurse practitioner entrepreneurs joint education and wider access to resources.
The pattern across October is clear. AI is being bought or licensed at every stage of the value chain, from molecule design to trial recruitment to the instruments that generate the data. Manufacturers and distributors are signing capacity and logistics agreements early, and diagnostics companies are embedding themselves in drug development programmes. With the Viatris–Pacira deal pending, acquisitions of commercial assets look set to remain part of the strategic toolkit alongside partnerships in the months ahead.